Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03609567 · ClinicalTrials.gov registry record · NA

Aromatherapy as Treatment for n/v of Pregnancy

A NA study of Pregnancy Emesis, sponsored by Albany Medical College.

Completed
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT03609567: Completed NA study of Pregnancy Emesis, sponsored by Albany Medical College.

NCT03609567 is a NA study of Pregnancy Emesis that has completed, run by Albany Medical College. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03609567, a NA study of Pregnancy Emesis, has completed, sponsored by Albany Medical College.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

A double-blinded randomized controlled trial comparing essential oil aromatherapy versus placebo for treatment of first trimester nausea and vomiting of pregnancy.

Primary Outcome

PUQE score is a validated measure of nausea and vomiting in pregnancy. It is a reliable tool used to measure the severity of nausea and vomiting of pregnancy. It is a questionnaire that measures the number of times in 24 hours a patient wretches, vomits, or feels nauseous. The minimum score is 3, and the maximum is 15. Participants will have PUQE scores calculated at baseline (during enrollment in the first trimester of pregnancy, at whatever age they are at), and after one month of aromatherapy

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Aromatherapy

Study Locations (1)

New York

  • Albany Medical Center - Albany

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2017-06-01
Est. Completion 2019-03-01
Phase NA
Albany Medical College

52 total trials

What the finished NCT03609567 record still lists

NCT03609567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Pregnancy Emesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03609567 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03609567 about?

NCT03609567 is a clinical study titled "Aromatherapy as Treatment for n/v of Pregnancy". A double-blinded randomized controlled trial comparing essential oil aromatherapy versus placebo for treatment of first trimester nausea and vomiting of pregnancy.

What is the current status of trial NCT03609567?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2017-06-01. Estimated completion is 2019-03-01.

What conditions does trial NCT03609567 study?

This clinical trial studies the following conditions: Pregnancy Emesis.

What interventions are being tested in trial NCT03609567?

The interventions under investigation include: Placebo (OTHER), Aromatherapy (OTHER).

Who is sponsoring clinical trial NCT03609567?

This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03609567 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy Emesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03609567's enrollment target sits among peer trials

17 1871st of 2000 higher than 130 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03609567, the US trial registry maintained by the National Library of Medicine. NCT03609567 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.